Skip to search formSkip to main contentSkip to account menu

XL880

Known as: XL 880, XL-880, XL880 cpd 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

GSK 1363089Organic Chemicals
foretinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Abstract 3042: LY2801653: An orally bioavailable MET kinase inhibitor with inhibitory activity against the oncoproteins ROS1 and MKNK1/2.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Under normal conditions MET receptor activation… 
2009
2009
State-ofthe-art treatment of metastatic renal cell carcinoma
s+%26+Virtual+Meeting/Abstracts?&vmview=abst_ detail_view&confID=47&abstractID=33225; cited January 19, 2009] 47. Rixe O… 
2008
2008
Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study
4572 Background: XL880 is a potent, orally available small molecule inhibitor of MET and VEGFR2/KDR. Gastric cancer cell lines… 
Highly Cited
2007
Highly Cited
2007
A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)
5103 Background: XL880 is a potent, orally available small molecule inhibitor of MET and VEGFR2/KDR. Activating mutations and/or… 
2007
2007
Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors
3526 Background: XL880 is a sub-nM inhibitor of the hepatocyte growth factor receptor (Met) and VEGF receptor family with low in… 
2007
2007
Gateways to clinical trials.
(-)-Epigallocatechin gallate, [188Re]-P2045, 12B75, 89-12; Abacavir sulfate/lamivudine, Abatacept, Abiraterone acetate, ABT-869… 
2006
2006
A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs).
3041 Background: XL880 is a sub-nM inhibitor of the hepatocyte growth factor receptor (Met) and vascular endothelial growth… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)